by European School of Oncology Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T-DM1—a drug that combines trastuzumab with an anti-cancer drug called DM1. Dr. Benedetta Conte, a medical oncology resident from the University of...